The place of targeted therapies in the management of non-small cell bronchial carcinoma

Rosell, Rafael; Morán, Teresa; Salazar, María Fernanda; Méndez, Pedro Rafael Casado; Aguirre, Itziar de; Ramirez, José Luis; Isla, Dolores; Cobo, Manuel; Camps, Carlos; López-Vivanco, G.; Alberola, Vicente; Tarón, Miguel

doi:10.1016/s0761-8425(06)72061-7

Cited by 5 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, extensive studies have shown that LUAD, as a type of non‐small cell carcinoma, comprises a typical tumor that can benefit from targeted molecular therapies [23–25]. In the present study, we found for the first time that the expression of ALMS1‐IT1 and AVL9 was both markedly elevated in LUAD, and there was a co‐expression relationship between ALMS1‐IT1 and AVL9.…”

Section: Discussionsupporting

confidence: 70%

The lncRNA ALMS1‐IT1 may promote malignant progression of lung adenocarcinoma via AVL9‐mediated activation of the cyclin‐dependent kinase pathway

Luan

Zhang

et al. 2021

FEBS Open Bio

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 70%

The lncRNA ALMS1‐IT1 may promote malignant progression of lung adenocarcinoma via AVL9‐mediated activation of the cyclin‐dependent kinase pathway

Luan

Zhang

et al. 2021

FEBS Open Bio

View full text Add to dashboard Cite

show abstract

Expression of short‐form oncostatin M receptor as a decoy receptor in lung adenocarcinomas

Chen

Chu

Chen

et al. 2008

The Journal of Pathology

View full text Add to dashboard Cite

Oncostatin M (OSM) is a member of the interleukin-6 (IL-6) family of cytokines, and binds to the OSM receptor (OSMR) to inhibit cancer growth. Four forms of OSMR have been identified: leukemia inhibitory factor receptor (LIFR), OSMR beta, short-form OSMR (OSMRs) and soluble OSMR (sOSMR). In this study, we examined the type and expression of OSMR in lung adenocarcinomas (LADCs). Expression of OSMR was determined by reverse transcription-polymerase chain reaction (RT-PCR), immunoblotting, immunohistochemistry and confocal immunofluorescent microscopy (CIM). Our results showed that, among the four forms of OSMR, OSMRs was mainly expressed in LADC, and expression level of OSMRs correlated with patient survival. CIM revealed that OSMRs was localized on the cell membrane of LADC cell lines in vitro. OSMRs acts as a decoy receptor by reducing the inhibitory effect of OSM on cell growth. Decrease in OSMRs expression by siRNA increased cell sensitivity to OSM, and ectopic expression of OSMRs reduced cell sensitivity to OSM. These results suggest that expression of OSMRs, which operates as a decoy receptor for OSM, is correlated with disease progression and adverse prognosis in patients with LADC.

show abstract

Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti‐apoptotic activity in lung adenocarcinoma cells

et al. 2011

View full text Add to dashboard Cite

By screening mouse monoclonal antibody libraries for Kelch repeats, we serendipitously identified monoclonal antibodies to eukaryotic elongation factor 2 (eEF2). Interestingly, eEF2 was highly expressed in lung adenocarcinoma (LADC), but not in the neighboring non-tumor lung tissue. Normally, eEF2 is involved in the peptidyl-tRNA translocation during protein synthesis. Overexpression of eEF2 would implicate an association with disease progression of LADC. In the present study, we investigated the prognostic significance of eEF2 in patients with LADC. Expression of eEF2 was detected by immunoblotting, immunohistochemistry and confocal immunofluorescence microscopy. Our results show that patients with high eEF2 expression had a significantly higher incidence of early tumor recurrence (67.8% vs 18.2%, P = 0.016), and a significantly worse prognosis (P < 0.001). In an in vitro study, silencing of eEF2 expression increased mitochondrial elongation, cellular autophagy and cisplatin sensitivity. Moreover, eEF2 was sumoylated in LADC cells, and eEF2 sumoylation correlated with drug resistance. These results suggest that eEF2 is an anti-apoptotic marker in LADC. However, biological function and involvement of eEF2 in the disease progression of LADC require further studies. (Cancer Sci 2011; 102: 1582-1589 H igh metastatic potential and cell growth rate, as well as resistance to irradiation and anticancer chemotherapeutic agents are major characteristics of lung adenocarcinoma (LADC).(1) To determine whether the malignant characteristics correlated with specific gene expression, we had used different methods to screen gene expression profiles, and we identified several genes of interest such as dihydrodiol dehydrogenase, hepatocyte growth factor (HGF), HGF receptor (or c-Met, a product of proto-oncogene c-met), dynamin-related protein 1 (DRP1) and ATPase family, AAA domain containing 3A (ATAD3A).(2-6) Among these genes, the protein level, but not the mRNA level, of ATAD3A was increased when LADC cells were exposed to the hypoxic condition, suggesting that translation efficacy was altered under such circumstance. (6,7) Protein translation factors, for example, eukaryotic protein initiation factor 4E (eIF4E) and protein elongation factor 1A2 (eEF1A2), have been shown to be associated with oncogenesis. (8,9) Their expression correlates with tumor cell growth, invasion, metastasis and hence a poor prognosis in lung, breast, ovarian cancer and acute myeloid leukemia.(10-13) When screening mouse monoclonal antibody libraries for Kelch repeats, (14) we serendipitously found monoclonal antibodies to eukaryotic elongation factor 2 (eEF2), a 95 kDa protein that catalyzed translocation of peptidyl-tRNA on the ribosome during the elongation phase of translation.(15) However, the effect of eEF2 has not been determined in LADC.In this report, we studied eEF2 expression in LADC specimens by immunoblotting and immunohistochemistry. We statistically evaluated the correlation between eEF2 expression and clinicopathological parameters, as w...

show abstract

The place of targeted therapies in the management of non-small cell bronchial carcinoma

Cited by 5 publications

References 31 publications

The lncRNA ALMS1‐IT1 may promote malignant progression of lung adenocarcinoma via AVL9‐mediated activation of the cyclin‐dependent kinase pathway

The lncRNA ALMS1‐IT1 may promote malignant progression of lung adenocarcinoma via AVL9‐mediated activation of the cyclin‐dependent kinase pathway

Expression of short‐form oncostatin M receptor as a decoy receptor in lung adenocarcinomas

Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti‐apoptotic activity in lung adenocarcinoma cells

Contact Info

Product

Resources

About